Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB0680 : HKBMM  update : 2022/06/30
CommentHuman cell line derived from malignant meningioma.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Ishiwata, Isamu
Originator Ishiwata, Isamu & Satou, Zenrou & Ishikawa, Hiroshi
Year of deposit 1991
Animal human < Mammals
Genus Homo
Species sapiens
Gender Female
Age at sampling 48 years
Tissue brain
Disease name malignant meningioma
Classification cancer
Year of origin 1991
Memo_1 Mycoplasma was eliminated with MC-210 by the depositor.
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_8162
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives HamF12 + 15% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Isozyme LD, NP
Chromosome mode 46-100(50) : 46(1),47(12),48(19),50(6),96(1),99(2)/
STR(human) OK
Images
deposit info
lot info
Reference information Reference 0
User's Publication 5


To topTop
Reference

To topTop
User's Publication
20220  Yamazaki S, Ohka F, Hirano M, Shiraki Y, Motomura K, Tanahashi K, Tsujiuchi T, Motomura A, Aoki K, Shinjo K, Murofushi Y, Kitano Y, Maeda S, Kato A, Shimizu H, Yamaguchi J, Adilijiang A, Wakabayashi T, Saito R, Enomoto A, Kondo Y, Natsume A.  Newly Established Patient-derived Organoid Model of Intracranial Meningioma.  Neuro Oncol  2021    PubMed ID: 34214169
20472  Yamamoto M, Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Sato A, Okada M, Kitanaka C.  Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.  Neurooncol Adv  2021  3(1):vdab148  PubMed ID: 34765973
16134  Yamamoto M, Sanomachi T, Suzuki S, Uchida H, Yonezawa H, Higa N, Takajo T, Yamada Y, Sugai A, Togashi K, Seino S, Okada M, Sonoda Y, Hirano H, Yoshimoto K, Kitanaka C.  Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma  Neuro Oncol   2021  23(6):945-954  PubMed ID: 33556172
11276  Ichikawa M, Akimoto J, Miki Y, Maeda J, Takahashi T, Fujiwara Y, Kohno M.  Photodynamic therapy with talaporfin sodium induces dose- and time-dependent apoptotic cell death in malignant meningioma HKBMM cells.  Photodiagnosis Photodyn Ther  2019    PubMed ID: 30389626
14614  Takeda H, Okada M, Kuramoto K, Suzuki S, Sakaki H, Sanomachi T, Seino S, Yoshioka T, Hirano H, Arita K, Kitanaka C.  Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo  Oncotarget  2017  8(53):90996-91008  PubMed ID: 29207619



Back Back Return Top Page